Back to top
more

Amicus Therapeutics (FOLD)

(Real Time Quote from BATS)

$6.78 USD

6.78
1,715,041

-0.15 (-2.17%)

Updated Aug 7, 2025 01:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks News

Zacks Equity Research

Tilray (TLRY) to Report Q3 Earnings: What's in the Cards?

Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports third-quarter 2019 results.

Zacks Equity Research

CannTrust (CTST) to Report Q3 Earnings: What's in Store?

On CannTrust's (CTST) third-quarter earnings call, investor focus will be on the company's efforts to regain licenses for producing and selling cannabis.

Zacks Equity Research

What's in Store for Cumberland Pharma (CPIX) in Q3 Earnings?

Cumberland Pharmaceuticals' (CPIX) third-quarter results are expected to reflect solid sales growth.

Zacks Equity Research

Zoetis (ZTS) to Report Q3 Earnings: What's in the Cards?

Zoetis (ZTS) is expected to provide pipeline updates during the third-quarter earnings call.

Zacks Equity Research

PCTEL (PCTI) Gears Up for Q3 Earnings: What's in Store?

PCTEL's (PCTI) third-quarter performance is likely have benefited from the demand for 5G scanning receivers and Industrial IoT antenna project wins.

Zacks Equity Research

What's in the Cards for Zynerba (ZYNE) This Earnings Season?

Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to have increased in the third quarter driven by clinical studies on its lead pipeline candidate, Zygel.

Zacks Equity Research

Amicus Therapeutics (FOLD) Expected to Beat Earnings Estimates: Should You Buy?

Amicus Therapeutics (FOLD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

CenturyLink (CTL) Gears Up for Q3 Earnings: What's in Store?

CenturyLink's (CTL) third-quarter performance is likely to have benefited from its focus on improving revenues while continuing deleveraging and cost-transformation initiatives.

Zacks Equity Research

Why Is Amicus Therapeutics (FOLD) Down 18.9% Since Last Earnings Report?

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Amicus (FOLD) Q2 Earnings Match, Stock Falls on Weak Q3 View

Amicus' (FOLD) earnings meet estimates in the second quarter while revenues beat the same.

Zacks Equity Research

Amicus Therapeutics (FOLD) Reports Q2 Loss, Tops Revenue Estimates

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 0.00% and 7.32%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Amicus Therapeutics (FOLD) to Report a Decline in Earnings: What to Look Out for

Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Why Is Amicus Therapeutics (FOLD) Down 9.6% Since Last Earnings Report?

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Amicus' (FOLD) Earnings & Revenues Miss Estimates in Q1

Amicus (FOLD) reports wider-than-expected loss in the first quarter of 2019. Also, sales miss estimates.

Zacks Equity Research

Amicus Therapeutics (FOLD) Reports Q1 Loss, Lags Revenue Estimates

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -25.81% and -9.90%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

What's in Store for Catalyst Pharma (CPRX) Q1 Earnings?

Catalyst Pharma (CPRX) is expected to announce revenue results on its lead product, Firdapse, when it releases first-quarter 2019 earnings performance.

    Zacks Equity Research

    Analysts Estimate Amicus Therapeutics (FOLD) to Report a Decline in Earnings: What to Look Out for

    Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Zacks Equity Research

    Amicus Therapeutics (FOLD) Up 12.4% Since Last Earnings Report: Can It Continue?

    Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Zacks Equity Research

    Amicus (FOLD) Reports Wider-than-Expected-Loss for 2018

    Amicus (FOLD) reports wider-than-expected loss in 2018, while revenues exceed estimates.

    Zacks Equity Research

    What's in Store for Universal Health (UHS) Q4 Earnings?

    Universal Health's (UHS) earnings in the fourth quarter are likely to gain from higher admissions and patient days.

    Zacks Equity Research

    What's in Store for Teladoc's (TDOC) Q4 Earnings?

    Teladoc's (TDOC) Q4 earnings might suffer high expenses, partly offset by rise in revenues.

    Zacks Equity Research

    Amicus Therapeutics (FOLD) Expected to Beat Earnings Estimates: Should You Buy?

    Amicus Therapeutics (FOLD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Zacks Equity Research

    Tenet Healthcare (THC) Q4 Earnings: What's in the Offing?

    Tenet Healthcare's (THC) Q4 earnings are likely to suffer lower admissions due to divestitures.

    Zacks Equity Research

    Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?

    Zoetis Inc. (ZTS) is gearing up to report fourth-quarter 2018 results. The company continues to strengthen its diverse product portfolio through lifecycle innovations, strong customer relationships, and access to new markets and technologies.

    Zacks Equity Research

    Amicus (FOLD) Boasts Strong Pipeline Amid Stiff Competition

    Amicus (FOLD) is well placed after the United States approved its only marketed drug, Galafold, and the company added 14 new gene therapy programs to its pipeline for rare metabolic diseases.